University of Kansas

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Northwestern University

Duke University

The Scripps Research Institute

Southern Research Institute

California Institute of Technology

The General Hospital Corporation

Oregon Health & Science University

The Broad Institute, Inc.

Uwm Research Foundation, Inc.

Cleave Biosciences, Inc.

Cannon Design, Inc.

Frank John Schoenen

Kevin Frankowski

Jeffrey Aube

Juan Jose Marugan

Wei Ping Zheng

Noel Terrence Southall

Samarjit Patnaik

George S Wilson

William Scott Jeffress

Steven Andrew Rogers

Sui Huang

Kelin Li

Marc Ferrer

Thomas Edward Prisinzano

Chen Wang

John Thomas Norton

E Lucile White

Laura Bohn

Steven Titus

Patrick C Seed

Robert Smith

James Noah

Brooks Maki

Carlos C Goller

Han-Jie Zhou

Carl F Nathan

Samuel Gerritz

David E Fisher

Xin Hu

Lester A Mitscher

Raymond J Deshaies

Warren S Weiner

Paolo Bernardi

Paul Hanson

Jingbo Xiao

Wendy Westbroek

Ehud Goldin

Gerald Henry Lushington

Ellen Sidransky

Rizwan Haq

Patrick Faloon

Michael Forte

Tsui-Fen Chou

Shanshan He

Congcong He

Sudeshna Roy

Justina Sileikyte

Altea Rocchi

Soma Ray

Debasree Dutta

Soumen Paul

Lisa M Harlan-Williams

Roy A Jensen

Ben S Gold

Yuchi Chen

Chunjing Liu

Andrew D Hager

Gerald G Williams

David Norman Frick

Brian Scott Jonathan Blagg

Elma Aflaki

Tsanyang Liang

Maneesh Pingle

Zongyi Hu

Wei Zheng

Kevin J Frankowski

The invention provides a compound of formula (I): wherein R, R, R, and Rare as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof. 

Autophagy inducers for treatment of CNS conditions

The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP)

The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R, R, R, and Rare as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal. 

Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis

Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers. 

Heterocyclic compounds and methods of use thereof

A laboratory fume hood system for cooling at least one laboratory device located in an interior work area comprises a heat exchanger system having a heat exchanger in thermal communication with a primary fluid loop containing chilled fluid and a secondary fluid loop containing a cooling fluid which is in thermal communication the laboratory device. The primary fluid loop is located behind the fume hood wall and not in the interior work area.

Laboratory fume hood system having recessed heat exchanger system

This invention provides cephalosporin derivatives for killing or inhibiting the spread of microorganisms such as non-replicatingand in the treatment of infectious disease.

Cephalosporin derivatives and methods of use

Heat exchanger interface system

Provided herein are compounds of the formula (IV) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer. 

Inhibitors of the MITF molecular pathway

This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.

Ethoxyphenyl thienyl compounds and methods for the treatment of bacterial infections

Methods for the treatment of bacterial infections

The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.

Kappa opioid receptor effectors and uses thereof

The present invention discloses thioflavine S and primuline derivatives which inhibit hepatitis C virus helicase and protease activity. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions containing the aforementioned compounds and methods of treating an HCV infection.

HCV helicase inhibitors and methods of use thereof

Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are disclosed. The variables. R-R, m, n, o, and p are disclosed herein. The compounds are useful for treating Gaucher disease and inhibiting the onset of Gaucher disease symptoms in a patient having a GBA gene mutation and for treating Parkinson's disease. Pharmaceutical compositions containing compounds of Formula (I) and methods of treatment comprising administering compounds of Formula (I) are also disclosed. 

Salicylic acid derivatives useful as glucocerebrosidase activators

Growing community of inventors

Lawrence, KS, United States of America

Frank John Schoenen